In-Person Access Only | 4.00 CE/CME Credits

The University of Kansas Cancer Center Breast Cancer Year in Review is a condensed review of new data and advances published throughout the year and presented at key oncology meetings. It gives healthcare providers the opportunity to learn about the latest advances in oncology education and translate science into better patient care. This accredited meeting is hosted as an in-person conference only with on-demand access for registered attendees

Program Chairs

Jennifer Klemp, PhD, MPH, MA | The University of Kansas Cancer Center

Priyanka Sharma, MD | The University of Kansas Cancer Center

Program Speakers

Kristy A. Brown, PhD | University of Kansas Cancer Center 

Matthew Goetz, MD | Mayo Clinic 

Erin Cobain, MD | University of Michigan 

Ana Garrido-Castro, MD | Dana-Farber Cancer Institute, Harvard Medical School

Angela DeMichele, MD, MSCE, FASCO | Abramson Cancer Center, University of Pennsylvania

Kari Wisinski, MD | University of Wisconsin

Conference Agenda
Saturday, February 22, 2025

8:35 AM
Welcome and Exhibits

8:55 AM
Opening Remarks

9:00 AM
Non CME Presentation

9:45 AM
Systemic treatment of Stage I Hormone negative breast cancer:  Optimal regimens, timing and duration? Erin Cobain, MD | University of Michigan

10:10 AM
Immune related toxicities of Chemoimmunotherapy in early-stage breast cancer: risk stratification, management and future directions Angela DeMichele, MD, MSCE, FASCO | Abramson Cancer Center, University of Pennsylvania

10:35 AM
Break and Exhibits

10:55 AM
Optimizing use of available antibody drug conjugates for metastatic breast cancer Ana Garrido-Castro, MD | Dana-Farber Cancer Institute, Harvard Medical School

11:20 AM
Monday morning Ptacice Implications: Q&A and Case Discussion Erin Cobain, MD | University of Michigan Ana Garrido-Castro, MD | Dana-Farber Cancer Institute, Harvard Medical School Angela DeMichele, MD, MSCE, FASCO | Abramson Cancer Center, University of Pennsylvania

12:05 PM
Break and Exhibits

12:15 PM
Non CME Presentation

1:00 PM
Metabolic syndrome and obesity in breast cancer: Key signaling pathways and Impact on sensitivity to therapy Kristy A. Brown, PhD | University of Kansas Cancer Center

1:25 PM
Advanced Stage Hormone Positive Breast Cancer: Fine-Tuning Sequential Endocrine and Targeted Therapy Kari Wisinski, MD | University of Wisconsin

1:50 PM
Break and Exhibits

2:00 PM
Optimizing use of available antibody drug conjugates for metastatic breast cancer Matthew Goetz, MD | Mayo Clinic

2:25 PM
Monday morning Ptacice Implications: Q&A and Case Discussion Kristy A. Brown, PhD | University of Kansas Cancer Center Kari Wisinski, MD | University of Wisconsin Matthew Goetz, MD | Mayo Clinic

3:10 PM
Adjourn

Agenda Subject To Change. All times are CST.

• Learning Objectives

  • Determine best application of new targeted therapies in patients with early stage and metastatic disease

  • Discuss the advances in systemic therapy likely to change current practices for treatment of breast cancer

  • Know how to utilize genomic tools for systemic therapy decision making and prediction of treatment response.

  • Be familiar with germ-line genetic testing options for hereditary breast cancer, including advantages and disadvantages of extended panel testing

  • Evaluate local therapy options for operable breast cancer depending on stage, and the use of neoadjuvant therapy

  • Identify evidence-based recommendations for decreasing symptoms and improving quantity and/or quality of life in survivors

• Accreditation Information | 4.00 CE/CME Credits

  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  Nurses (ANCC) Credit Designation

  Amedco LLC designates this activity for a maximum of TBD ANCC contact hours.

  Physicians (ACCME) Credit Designation

  Amedco LLC designates this live activity for a maximum of 4.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

  Amedco LLC designates this activity for a maximum of 4.00 knowledge-based CPE contact hours.

  NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

• What to Expect | In-Person Learners

  • Free registration for all healthcare providers

  • Expert sessions that present the most clinically relevant data, research, and clinical strategies

  • Real-time discussion and debate

  • Networking with peers, colleagues, and medical professionals

  • Access to the latest industry information and resources

  • Catered meals through-out the program